Clinical Trials
25
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
- Conditions
- Advanced CancerMetastatic Cancer
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 1000
- Registration Number
- NCT06963723
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 178
- Registration Number
- NCT05798663
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Registration Number
- NCT05408026
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Medstar Georgetown Cancer Institute, Washington, District of Columbia, United States
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
- Conditions
- Hormone Sensitive Prostate CancerProstate Cancer MetastaticNon-metastatic Prostate CancerMetastatic Prostate CancerProstate CancerCastrate Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 111
- Registration Number
- NCT04335682
- Locations
- 🇺🇸
University of California - San Francisco at Mount Zion, San Francisco, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next